We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » ANALYST LOWERS PROJECTED REVENUES ON ANDRX'S CARDURA XL
ANALYST LOWERS PROJECTED REVENUES ON ANDRX'S CARDURA XL
June 23, 2004
The expected launch date of Pfizer’s new prostate gland drug Cardura XL (doxazosin mesylate), which will be distributed by generic firm Andrx, has been pushed back, according to a pharmaceutical analyst who lowered expected revenues on the brand product.